Skip to main content
SpringerLink
Log in

Antiangiogenic Chemotherapeutic Agents

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

The mechanism of action of anticancer chemotherapeutic agents is mainly thought to be due to a direct inhibition of tumor cell proliferation. The enhanced endothelial cell proliferation rate in tumor specimens raised the question whether therapeutic effects of chemotherapeutic agents might be at least partially attributed to an inhibition of tumor angiogenesis. Meanwhile, numerous anticancer chemotherapeutic agents were tested for their antiangiogenic potential. A few agents seem to exert consistent inhibition of tumor angiogenesis even in drug-resistant tumors. Most recent investigations on the antiangiogenic efficacy of different application schedules suggested the use of a tightly spaced, continuous application of appropriate anticancer chemotherapeutic agents. These application schedules are able to exert a strong antiangiogenic effect as indicated by an increase of apoptosis of tumor endothelial cells. Future clinical trials have to determine the therapeutic benefit of novel combination chemotherapy and alternative application schedules.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gilman A, Philips FS: The biological action and therapeutic application of beta-chloroethyl amines and sulfides. Science 103: 409-415, 1946

    Google Scholar 

  2. Skipper HE, Schabel Jr FM, Wilcox WS: Experimental evaluation of potential anticancer drugs. XII. On the criteria and kinetics associated with curability of experimental leukemia. Cancer Chemother Rep 35: 1-93, 1964

    Google Scholar 

  3. Norton L: A Gompertzian model of human breast cancer growth. Cancer Res 48: 7067-7071, 1988

    Google Scholar 

  4. Schirner M, Hoffmann J, Menrad A, Schneider MR: Antiangiogenic chemotherapeutic agents: Characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Clin Cancer Res 4: 1331-1336, 1998

    Google Scholar 

  5. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285: 1182-1186, 1971

    Google Scholar 

  6. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Nat Cancer Inst 82: 4-6, 1990

    Google Scholar 

  7. Brower V: Tumor angiogenesis-new drugs on the block. Nature Biotech 17: 963-968, 1999

    Google Scholar 

  8. Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nica B, Ria R, Pellegrino A, Dammacco F: Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94: 4143-4155, 1999

    Google Scholar 

  9. Kerbel RS: Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 13: 31-36, 1991

    Google Scholar 

  10. Tannock I: Population kinetics of carcinoma cells, capillary endothelial cells and fibroblasts in a transplanted mouse mammary tumor. Cancer Res 30: 2470-2476, 1970

    Google Scholar 

  11. Hobson B, Denekamp J: Endothelial cell proliferation in tumors and normal tissue: continuous labelling studies. Br J Cancer 49: 405-413, 1984

    Google Scholar 

  12. Fox SB, Gatter KC, Bicknell R, Going JJ, Stanton P, Cooke TG, Harris AL: Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res 53: 4161-4163, 1993

    Google Scholar 

  13. Denekamp J: Endothelial cell proliferation as a novel approach to targeting tumor therapy. Br J Cancer 45: 136-139, 1982

    Google Scholar 

  14. Lazo JS: Endothelial injury caused by antineoplastic agents. Biochem Pharmacol 35: 1919-1923, 1986

    Google Scholar 

  15. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ: Vinca alkaloids: anti-vascular effects in a murine tumor. Eur J Cancer 29: 1320-1324, 1993

    Google Scholar 

  16. Orr FW, Adamson IYR, Young L: Promotion of pulmonary metastasis in mice by bleomycin-induced endothelial injury. Cancer Res 46: 891-897, 1986

    Google Scholar 

  17. Harrison JH, Lazo JS: High dose continuous infusion of bleomycin in mice: A new model for drug-induced pulmonary fibrosis. J Pharmacol Exp Ther 243: 1185-1194, 1988

    Google Scholar 

  18. Hill SA, Sampson LE, Chaplin DJ: Anti-vascular approaches to solid tumor therapy: Evaluation of vinblastin and flavone acid. Int J Cancer 63: 119-123, 1995

    Google Scholar 

  19. Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ: Inhibition of growth of colon 38 adenocarcinoma by vinblastin and cholchicin: Evidence for a vascular mechanism. Eur J Cancer 27: 482-487, 1991

    Google Scholar 

  20. Belotti D, Vergani V, Drudis T, Borsotti P, Piletti MR, Viale G, Giavazzi R, Taraboletti G: The microtuble-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2: 1843-1849, 1996

    Google Scholar 

  21. Klauber N, Parangi S, Flynn E, Hamel E, D´Amato RJ: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitor 2-methoxyestradiol and taxol. Cancer Res 57: 81-86, 1997

    Google Scholar 

  22. Lau DH, Xue L, Young LJ, Burke PA, CheungAT: Paclitaxel (taxol): An inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 14: 31-36, 1999

    Google Scholar 

  23. Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O´Reilly MS, Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878-1886, 2000

    Google Scholar 

  24. Steiner R: Angiostatic activity of anticancer agents in the chick embryo chorioallantoic membrane (CHE-CAM) assay. In: Steiner R, Weisz PB, Langer R (eds) Angiogenesis, Birkhäuser Verlag, Basel, 1992, pp 449-454

    Google Scholar 

  25. Maragoudarkis ME, Peristeris P, Missirlis E, Aletras A, Andriopolou P, Haralabopoulous G: Inhibition of angiogenesis by anthracyclines and titanocene dichloride. Ann NY Acad Sci 732: 280-293, 1994

    Google Scholar 

  26. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman, J: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348: 555-557, 1990

    Google Scholar 

  27. O´Leary JJ, Shapiro RL, Ren CJ, Chuang N, Cohen HW, Potmesil M: Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptpthecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res 5: 181-187, 1999

    Google Scholar 

  28. Yonekura K, Basaki Y, Chikahisa L, Okabe S, Hashimota A, Miyadera K, Wierzba K, Yamada Y: UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air say assay in mice. Clin Cancer Res 5: 2185-2191, 1999

    Google Scholar 

  29. Presta M, Rusnati M, Belleri M, Morbidelli L, Ziche M, Ribatti D: Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process. Cancer Res 59: 2417-2424, 1999

    Google Scholar 

  30. Iyer S, Chaplin DJ, Rosenthal DS, Boulares H, Li LY, Smulson ME: Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res 58: 4510-4514, 1998

    Google Scholar 

  31. Chaplin DJ, Pettit GR, Hill SA: Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A-4 phosphate. Anticancer Res 19: 189-196, 1999

    Google Scholar 

  32. Nasu R, Kimura H, Akagi K, MurataT, TanakaY: Blood flow influences vascular growth during tumour angiogenesis. Br J Cancer 79: 780-786, 1999

    Google Scholar 

  33. Teicher BA, Sotomayor EA, Huang ZD: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52: 6702-6704, 1992

    Google Scholar 

  34. Kato T, Sato K, Kakinuma H, Matsuda Y: Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamyl-fumagillol-TNP.470) and cytotoxic agents in mice. Cancer Res 54: 5143-5147, 1994

    Google Scholar 

  35. Arsenault AL, Lhotak S, Hunter WL, Banquerigo ML, Brahn E: Taxol involution of collagen-induced arthritis: Ultrastructural correlation with the inhibition of synovitis and neovascularization. Clin Immunol Immunopathol 86: 280-289, 1998

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Laboratories of Schering AG, Berlin, Germany

    Michael Schirner

Authors
  1. Michael Schirner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schirner, M. Antiangiogenic Chemotherapeutic Agents. Cancer Metastasis Rev 19, 67–73 (2000). https://doi.org/10.1023/A:1026500431505

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026500431505

Search

Navigation